14 results about "Nojirimycin" patented technology

The invention discloses a method for simultaneously extracting and separating flavonoid and alkaloid components in mulberry leaves, which comprises the following steps: firstly, adjusting the pH value of an aqueous solution of a deep eutectic solvent to form a uniform single-phase solution, adding mulberry leaf powder into the single-phase solution, carrying out ultrasonic extraction, centrifuging after the extraction is finished, and taking a supernatant; adjusting the pH value of the extracting solution again to form a two-phase system, and respectively obtaining an upper-layer eutectic solvent phase and a lower-layer water phase. The conditions of the extraction step are as follows: the concentration of the eutectic solvent is 30%-70%, the solid-to-liquid ratio is 1: 5 g / mL-1: 40 g / mL, the extraction time is 20 min-100 min, and the extraction pH is 5.5-9.5; in the separation step, the conditions of the separation step are as follows: the separation pH is 1-5. Through HPLC (High Performance Liquid Chromatography) analysis, a flavonoid component (isoquercitrin) is mainly distributed in an upper-layer deep-eutectic solvent phase, an alkaloid component (deoxynojirimycin) is mainly distributed in a lower-layer water phase, and the reusability is good.

The invention belongs to the technical field of biology, and discloses a transaminase GabT1 mutant S106I, a construction method thereof and application of the transaminase GabT1 mutant S106I in biosynthesis of 1-deoxynojirimycin. According to the invention, the 106th serine near the molecular catalytic domain of the transaminase GabT1 derived from bacillus amyloliquefaciens is mutated into isoleucine in a site-directed mutagenesis manner, so that the catalytic efficiency of the transaminase GabT1 is remarkably improved, the problem that the catalytic efficiency of the transaminase GabT1 on fructose-6-phosphoric acid is not high at present is solved, and the application of the transaminase GabT1 to the fructose-6-phosphoric acid is promoted. The yield of 1-deoxynojirimycin synthesized by the mutant GabTS106I is increased by 43.87% compared with that of a wild type. The 1-deoxynojirimycin fermentation production capability of the transaminase GabT1 mutant and the engineering strain obtained by the invention is greatly improved, and the transaminase GabT1 mutant and the engineering strain have a good industrial application prospect.

The application provides an amphiphilic nobeliatin molecule, a preparation method thereof and a blood glucose lowering and antibacterial application to a diabetic wound. The application relates to the technical field of biomedical materials. The application synthesizes a novel amphiphilic nobeliatin molecule by taking 1-deoxynobeliatin as a hydrophilic part and an alkyl chain as a hydrophobic part. The compound can self-assemble into a cluster sugar molecule in an aqueous solution, has good blood glucose lowering activity through the "multivalent effect" of the cluster sugar-glycosidase, has good antibacterial activity through the tertiary amine structure of the azasugar molecule and the long alkyl chain and the bacterial membrane, and realizes the compatibility of the blood glucose lowering effect and the antibacterial effect. The synthesis raw material of the nobeliatin molecule provided by the application is rich in source, low in price, simple in preparation process and convenient for industrial application. Therefore, the discovery of the compound is expected to provide a promising treatment scheme for the development of blood glucose lowering and antibacterial integrated materials and the treatment of diabetic wounds, and has a wide potential application field.

The invention relates to a 5-aminohexahydro-6,7,8-trihydroxy-3H-oxazo-lo[3,4-a]pyridin-3-one (i.e. 2,3,4-trihydroxy-5N,6O-oxomethylidene-nojirimycin-1-amine) glycol-ipid mimetic derivative of formula (I) acting as antagonists or agonist of the TLR4 for the treatment and / or prevention of an immune disease such as e.g. acute inflammation, chronic disease allergy, the Metabolic Syndrome, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), immune mediated hepatitis, an autoimmune disease, graft rejection pathology, inflammatory bowel disease, atherosclerosis and airway hyperactivity, such as e.g. asthma and allergic rhinitis. An exemplary compound is e.g. example 1, compound (1).

The invention provides an amphipathic nojirimycin molecule, a preparation method thereof and application of the amphipathic nojirimycin molecule in reducing blood glucose and resisting bacteria on diabetic wounds. The invention relates to the technical field of biomedical materials. According to the invention, 1-deoxynojirimycin is taken as a hydrophilic part, an alkyl chain is taken as a hydrophobic part, and a novel amphiphilic nojirimycin molecule is synthesized. The compound can be self-assembled into a cluster sugar molecule in an aqueous solution, and has good hypoglycemic activity through a'multivalent effect 'of cluster sugar-glycosidase; through the action of a tertiary amine structure of an azasugar molecule and a long alkyl chain with a bacterial membrane, the azasugar has good antibacterial activity, and compatibility of a hypoglycemic effect and an antibacterial effect is realized. The nojirimycin molecule provided by the invention is rich in synthesis raw material source, low in price, simple in preparation process and convenient for industrial application. Therefore, the discovery of the compound is expected to provide a promising treatment scheme for development of blood glucose reducing and antibacterial integrated materials and treatment of diabetic wounds, and the compound has a wide potential application field.

Disclosed are a 1-deoxynojirimycin derivative and use thereof. According to the present invention, a variety of 1-deoxynojirimycin derivatives are prepared and obtained through screening. Compared with 1-deoxynojirimycin as a lead compound, the 1-deoxynojirimycin derivative can better bind to an amino acid site that is related to a target protein OPA1, stabilize a binding pocket at a dimer interface, promote the formation of an OPA1 dimer and repair a mitochondrial ultrastructure, thereby significantly saving mitochondrial functions and effectively improving a physiological state of cells. The 1-deoxynojirimycin derivative of the present invention can be used for preparing a drug for treating a disease that is related to unbalanced formation of the OPA1 dimer, and for example, can be used as a potential therapeutic drug for mitochondrial cardiomyopathy and other mitochondrial diseases.

The invention belongs to the technical field of industrial biology, and discloses bacillus amyloliquefaciens capable of producing 1-deoxynojirimycin and application of the bacillus amyloliquefaciens to fermentation production of the 1-deoxynojirimycin. The yield of DNJ produced by fermentation of the bacillus amyloliquefaciens is high, the titer of the DNJ reaches 1.4 g / L or above, little foam is generated in the fermentation process, process control of industrial-grade large-scale fermentation is facilitated, the fermentation period is short, a culture medium formula is simple, and industrial production is facilitated.

The present invention discloses 1-deoxynojirimycin derivatives and their uses. Through screening, several 1-deoxynojirimycin derivatives were prepared. Compared with the lead compound 1-deoxynojirimycin, these derivatives better bind to the relevant amino acid site of the target protein OPA1 and are stabilized in the binding pocket of the dimer interface. They promote the formation of OPA1 dimers and restore mitochondrial ultrastructure, thereby significantly maintaining mitochondrial function and effectively improving cellular physiological status. The 1-deoxynojirimycin derivatives of the present invention are useful for preparing drugs for treating diseases associated with an imbalance in OPA1 dimer formation, and are promising therapeutic agents for, for example, mitochondrial cardiomyopathy and other mitochondrial diseases.

The invention provides a deoxynojirimycin-pterostilbene compound as well as a preparation method and application thereof, and relates to the technical field of medicinal chemistry. The deoxynojirimycin-pterostilbene compound provided by the invention has a structure as shown in a formula I, and n is the number of carbon and is selected from 2-6, 8, 10 or 12. The invention also provides the application of the deoxynojirimycin-pterostilbene compound in preparation of medicines for treating or preventing abnormal glucose and lipid metabolism diseases. According to the prepared deoxynojirimycin-pterostilbene compound, the adopted method has the advantages that raw materials are easy to obtain, operation is easy and convenient, and the yield is high, a target compound can be rapidly synthesized, and the target compound has the effect of reducing blood sugar and blood lipid.

The invention belongs to the technical field of functional foods, and particularly relates to an anti-inflammatory hypoglycemic food based on potato peptide and a preparation method thereof, and the preparation method comprises the following steps: S1, preparing potato peptide by taking potato protein as a raw material, and performing pretreatment, composite enzymolysis, centrifugal separation, ultrafiltration purification and spray drying to obtain small molecular potato peptide; s2, pretreatment of auxiliary materials: the prebiotics, the deoxynojirimycin, the functional sweetening agent, the dietary fibers, the compound vitamins and the compound minerals are crushed, screened or dissolved respectively, and the potato peptide is used as a core raw material, so that pancreatic beta cell proliferation can be promoted, insulin receptor sensitivity can be improved, the potato peptide directly acts on blood sugar regulation, and the effect of improving the insulin receptor sensitivity is achieved; the problem that an existing blood sugar reducing food only controls sugar and cannot intervene in the pain point of inflammation is solved, vicious circle of inflammation and hyperglycemia is avoided so as to meet the pathological requirements of diabetics, and the blood sugar reducing food is superior to traditional blood sugar reducing food depending on dietary fibers or single plant extracts.

The present invention relates to the technical field of extraction of mulberry leaves after frost, and in particular to an extraction method and application of an extract of mulberry leaves after frost. The extraction method sequentially includes pretreatment of mulberry leaves after frost, preparation of a composite enzyme aqueous solution, preparation of a hyaluronic acid aqueous solution, enzymatic hydrolysis treatment, and extraction of an extract of mulberry leaves after frost. Through specific selection of raw materials and cooperation with a specific extraction process, an extract of mulberry leaves after frost with a 1-deoxynojirimycin mass content as high as 5.2-7.0% is obtained; at the same time, it breaks through the limitation that the existing mulberry leaf extract needs to be stored under harsh conditions of 2-8°C. After the extract of mulberry leaves after frost extracted by a specific extraction process is stored in the dark at 18°C for 300 days, the retention rate of the mass content of 1-deoxynojirimycin it is rich in can be greater than or equal to 89%, further reducing the storage cost for its subsequent popularization as a hypoglycemic product.

The invention relates to the field of biomedicine and pharmacology, and provides an application of 1-deoxynojirimycin (DNJ) in activating mitochondrial ATP synthase to improve the myocardial function of diabetic cardiomyopathy. In-vivo experiments prove that the DNJ can obviously reduce the weight and fasting blood glucose level of diabetic mice, improve the cardiac function, relieve myocardial cell hypertrophy, relieve cardiac fibrosis and lipidation and inhibit oxidative stress and apoptosis. Meanwhile, in-vitro experiments prove that DNJ reduces the ROS level, recovers mitochondrial membrane potential and improves mitochondrial structure damage, and by activating mitochondrial ATP synthase, the heart ATP generation level is improved, and the mitochondrial function is recovered. In addition, DNJ also activates a PI3K / Akt signal channel and inhibits apoptosis of myocardial cells. As a natural plant component, DNJ has the advantages of small toxic and side effects and mild and lasting effect, and a new way is provided for prevention and treatment of diabetic cardiomyopathy.

The invention belongs to the technical field of biological medicines, and discloses a mulberry leaf deoxynojirimycin pharmaceutical composition for treating cancers. The pharmaceutical composition comprises an IFITM3 protein monoclonal antibody and mulberry leaf deoxynojirimycin, the amino acid sequence of an antibody light chain variable region of the IFITM3 protein monoclonal antibody is as shown in SEQ ID NO.3, and the amino acid sequence of an antibody heavy chain variable region of the IFITM3 protein monoclonal antibody is as shown in SEQ ID NO.4. In the monoclonal antibody and mulberry leaf deoxynojirimycin composition provided by the invention, the IFITM3 protein monoclonal antibody can be produced in batches, can be specifically combined with human IFITM3 protein, and has the effect of reducing the activity of gastric cancer cells; the mulberry leaf deoxynojirimycin is simple in extraction step and contains few impurities; after the IFITM3 protein monoclonal antibody and the mulberry leaf deoxynojirimycin are used together, the growth and migration ability of gastric cancer cells can be effectively inhibited within a short time, the medicine can be positioned to gastric cancer tissues after entering a human body, the gastric cancer can be treated and relapse can be prevented by inhibiting self-renewal and migration of the cancer cells, and the medicine has a relatively good medical application prospect.